SHARPS COMPLIANCE CORP (SMED)
US8200171010 - Common Stock
Taking everything into account, SMED scores 3 out of 10 in our fundamental rating. SMED was compared to 118 industry peers in the Health Care Providers & Services industry. While SMED seems to be doing ok healthwise, there are quite some concerns on its profitability. SMED is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SMED had positive earnings in the past year.
In multiple years SMED reported negative net income over the last 5 years.
SMED had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.89% | ||
| ROE | 4.19% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -0.78% | ||
| PM (TTM) | 3.25% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMED has more shares outstanding
Compared to 1 year ago, SMED has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.14 indicates that SMED is not in any danger for bankruptcy at the moment.
SMED has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.14 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 3.50 indicates that SMED has no problem at all paying its short term obligations.
A Quick Ratio of 3.03 indicates that SMED has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.5 | ||
| Quick Ratio | 3.03 |
3. Growth
3.1 Past
SMED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.24%.
SMED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 312.69% yearly.
Looking at the last year, SMED shows a quite strong growth in Revenue. The Revenue has grown by 18.16% in the last year.
The Revenue has been growing by 18.02% on average over the past years. This is quite good.
EPS 1Y (TTM)-67.24%
EPS 3Y687.4%
EPS 5Y312.69%
EPS growth Q2Q-102.5%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y23.94%
Revenue growth 5Y18.02%
Revenue growth Q2Q-36.15%
3.2 Future
The Earnings Per Share is expected to grow by 21.25% on average over the next years. This is a very strong growth
SMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.23% yearly.
EPS Next Y-96.71%
EPS Next 2Y-62.6%
EPS Next 3Y-24.65%
EPS Next 5Y21.25%
Revenue Next Year-19.46%
Revenue Next 2Y-8.94%
Revenue Next 3Y-2.26%
Revenue Next 5Y1.23%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 46.05, which means the current valuation is very expensive for SMED.
The average S&P500 Price/Earnings ratio is at 28.91. SMED is valued rather expensively when compared to this.
SMED is valuated quite expensively with a Price/Forward Earnings ratio of 100.92.
SMED is valuated expensively when we compare the Price/Forward Earnings ratio to 20.51, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.05 | ||
| Fwd PE | 100.92 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 86.22 |
4.3 Compensation for Growth
A cheap valuation may be justified as SMED's earnings are expected to decrease with -24.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.15
EPS Next 2Y-62.6%
EPS Next 3Y-24.65%
5. Dividend
5.1 Amount
SMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SHARPS COMPLIANCE CORP
NASDAQ:SMED (8/22/2022, 7:00:03 PM)
8.75
+0.01 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap170.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.05 | ||
| Fwd PE | 100.92 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.89% | ||
| ROE | 4.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | -0.78% | ||
| PM (TTM) | 3.25% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.5 | ||
| Quick Ratio | 3.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-67.24%
EPS 3Y687.4%
EPS 5Y
EPS growth Q2Q
EPS Next Y-96.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.16%
Revenue growth 3Y23.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y